UG Healthcare Corporation Ltd Sees Net Loss For HY23

Jan 31 (Reuters) - UG Healthcare Corporation Ltd : * SEES NET LOSS FOR HY23 * EXPECTED RESULT DUE TO HIGHER OPERATING EXPENSES AT UPSTREAM MANUFACTURING OF DISPOSABLE EXAMINATION GLOVES, AMONG OTHERS

Drugmakers prevail in dispute over U.S. discount drug program

By Brendan Pierson Jan 30 (Reuters) - Drug manufacturers can limit healthcare providers' use of outside pharmacies for dispensing drugs under a federal drug discount program, a federal appeals court

Gamida Cell To Cancel Special Meeting Of Shareholders

Jan 30 (Reuters) - Gamida Cell Ltd: * GAMIDA CELL LTD - HAS DETERMINED TO CANCEL SPECIAL MEETING OF SHAREHOLDERS PREVIOUSLY SCHEDULED FOR FEBRUARY 14, 2023 Source text: (https://bit.ly/3JtPq1B)

Evoke Announces Teva Ends Pursuit Of Paragraph IV ANDA Against Gimoti

Jan 30 (Reuters) - Evoke Pharma Inc: * EVOKE ANNOUNCES TEVA ENDS PURSUIT OF PARAGRAPH IV ANDA AGAINST GIMOTI * EVOKE PHARMA - IN ADDITION, NO FUTURE ANDA FILER WILL BE ELIGIBLE TO RECEIVE 180-DAY

Daiichi Sankyo Says Tropion-Lung07 Phase 3 Trial Initiated

Jan 30 (Reuters) - Daiichi Sankyo Co Ltd: * TROPION-LUNG07 PHASE 3 TRIAL INITIATED TO EVALUATE DATOPOTAMAB DERUXTECAN IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED METASTATIC

May & Baker Nigeria Reports Qtrly Group PBT From Cont Ops 414.4 Mln Naira

Jan 30 (Reuters) - May & Baker Nigeria PLC: * MAY & BAKER NIGERIA PLC- QTRLY GRP PBT FROM CONTINUING OPERATIONS 414.4 MILLION NAIRA VERSUS 162.7 MILLION NAIRA * MAY & BAKER NIGERIA PLC - QTRLY GROUP

All countries 'dangerously unprepared' for future pandemics, says IFRC

GENEVA (Reuters) - The world is "dangerously unprepared" for future pandemics, the International Federation of the Red Cross and Red Crescent Societies (IFRC) say in a report published on Monday,

Alterity's ATH434 Prevents Loss Of Brain Cells In Parkinson's Disease Animal Model

Jan 30 (Reuters) - Alterity Therapeutics Ltd: * ALTERITY’S ATH434 PREVENTS LOSS OF BRAIN CELLS IN PARKINSON’S DISEASE ANIMAL MODEL Further company coverage:

Bionomics Ltd Has Sufficient Cash Runway To Support Its Ongoing Activities

Jan 30 (Reuters) - Bionomics Ltd: * BIONOMICS LTD- HAS SUFFICIENT CASH RUNWAY TO SUPPORT ITS ONGOING ACTIVITIES AND UPCOMING MILESTONES WITH RUNWAY TO AT LEAST MID-2024 Further company coverage:

Novartis AG <NOVN.S>: Profits of $1.4 per share anticipated for fourth quarter

30 January 2023 11:07 a.m. All figures in US dollars. Novartis AG is expected to show a decrease in its fourth quarter earnings to $1.40​ per share according to the mean Refinitiv estimate from nine